ENDRA Life Sciences Inc. financial data

Symbol
NDRA on Nasdaq
Industry
Electromedical & Electrotherapeutic Apparatus
Location
3600 Green Court, Suite 350, Ann Arbor, MI
State of incorporation
DE
Fiscal year end
December 31
Former names
Endra Inc. (to 9/21/2016)
Latest financial report
10-K/A - Q4 2024 - Apr 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 411 % +23.8%
Quick Ratio 204 % +30.2%
Debt-to-equity 29.6 % -17.2%
Return On Equity -211 % -16.6%
Return On Assets -162 % -22.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 562K shares -94.9%
Common Stock, Shares, Outstanding 537K shares
Entity Public Float 7.01M USD -31.6%
Common Stock, Value, Issued 53 USD

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 3.19M USD -36.2%
Selling and Marketing Expense 571K USD -30.4%
General and Administrative Expense 7.06M USD +50.2%
Operating Income (Loss) -10.8M USD -2.82%
Nonoperating Income (Expense) -845K USD -3094%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -11.5M USD -14.4%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -11.5M USD -14.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.82M USD
Inventory, Net 0 USD -100%
Assets, Current 3.43M USD +13.2%
Property, Plant and Equipment, Net 69.3K USD -38%
Operating Lease, Right-of-Use Asset 578K USD +63.2%
Assets 4.45M USD -34.1%
Accounts Payable, Current 270K USD -25.2%
Employee-related Liabilities, Current 63.1K USD -58%
Liabilities, Current 605K USD -33%
Operating Lease, Liability, Noncurrent 487K USD +154%
Liabilities 1.89M USD +72.8%
Retained Earnings (Accumulated Deficit) -103M USD -12.5%
Stockholders' Equity Attributable to Parent 2.56M USD -54.8%
Liabilities and Equity 4.45M USD -34.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.14M USD +14.5%
Net Cash Provided by (Used in) Financing Activities 469K USD
Net Cash Provided by (Used in) Investing Activities -23.8K USD +11.9%
Common Stock, Shares Authorized 20M shares 0%
Common Stock, Shares, Issued 537K shares
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.53M USD -8.55%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.23M USD +14%
Interest Paid, Excluding Capitalized Interest, Operating Activities 8.8K USD
Deferred Tax Assets, Valuation Allowance 24.6M USD +16.1%
Operating Lease, Liability 584K USD +59.7%
Depreciation 11.5K USD -64.1%
Payments to Acquire Property, Plant, and Equipment 27K USD 0%
Lessee, Operating Lease, Liability, to be Paid 733K USD +80.8%
Property, Plant and Equipment, Gross 580K USD -12%
Operating Lease, Liability, Current 96.9K USD -44.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 203K USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year One 153K USD -24.6%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 148K USD +277%
Lessee, Operating Lease, Liability, to be Paid, Year Three 203K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 19.6M USD +17.9%
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 106M USD +8.62%
Depreciation, Depletion and Amortization 34.5K USD +81.3%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Operating Leases, Future Minimum Payments Due 406K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%